A Phase I/II Randomized, Prospective, Double-blind, Placebo-controlled, Single-center Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells
Latest Information Update: 27 Sep 2024
At a glance
- Drugs MV 130 (Primary)
- Indications Bacterial infections; Bronchiectasis; COVID-19 pneumonia; Viral infections
- Focus Pharmacodynamics
- Sponsors Inmunotek
Most Recent Events
- 19 Sep 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2025.
- 19 Sep 2024 Planned primary completion date changed from 30 Sep 2023 to 30 Jan 2025.
- 19 Sep 2024 Status changed from not yet recruiting to recruiting.